1. Month-in-Review Snapshot — August 2025 packed a decade’s worth of lab, clinic, and policy progress into 31 days August 2025 emerged as a landmark month for cell therapy, with pivotal developments spanning from foundational science to late-stage clinical trials and crucial regulatory shifts. The momentum for ‘off-the-shelf’ therapies surged as Wugen, Inc. secured $115 … Continue reading Cell-Therapy Flashpoint: Off-the-Shelf Breakthroughs, CRISPR-Tuned NK Cells, and Access Wins Signal a New Commercial Era